Fig. 4. LINC00562 targeted miR-4636.
(A) LncBase (
https://diana.e-ce.uth.gr/lncbasev3) predicted LINC00562–miR-4636 binding sites. (B) Putative binding sites were validated using dual-luciferase assays, **p < 0.01 in contrast to miR-NC. (C) Binding of LINC00562 to miR-4636 was confirmed by RIP assay, **p < 0.01 in contrast to Anti-IgG. (D) MiR-4636 expression levels in tumor and normal specimens. (E) MiR-4636 expression levels in GES-1, RGM-1, and GC cells (HGC-27 and AGS), **p < 0.01 in contrast to GES-1. (F) Correlation between miR-4636 expression and LINC00562 expression in tumor samples was determined using Pearson’s analysis. Values are presented as mean ± SD. GC, gastric cancer.
